Peer-reviewed veterinary case report
Oral docetaxel and cyclosporine for treating dog epithelial cancer
By Waite, A et al.·Published in Veterinary and comparative oncology·2014·Cornell University Hospital for Animals, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer.
- Species:
- dog
Plain-English summary
A group of 51 dogs with epithelial cancer (a type of skin or tissue cancer) was treated with a combination of oral docetaxel and cyclosporine to see if it would help. While some dogs experienced side effects like stomach issues, 8 out of 48 dogs showed a partial response to the treatment, particularly those with oral squamous cell carcinoma, where half of the affected dogs improved. Unfortunately, the overall success rate was low, and some dogs had to stop treatment due to complications.
People also search for: dog cancer treatment options · oral squamous cell carcinoma in dogs · docetaxel for dogs cancer · side effects of cyclosporine in dogs
Abstract
The goal of the current study was to determine the efficacy of oral docetaxel in combination with cyclosporine in the treatment of canine epithelial cancer. Requirements for eligibility were histological confirmation of epithelial neoplasia, measurable disease, no chemotherapy treatment within 2 weeks, and a life expectancy of ≥ 3 months. Fifty-one dogs were enrolled. All dogs received 1.625 mg kg(-1) of docetaxel with 5 mg kg(-1) of cyclosporine (DT/CSA) by gavage. Ten dogs had progressive disease at 2 weeks, one dog died, and one dog was withdrawn from the study. Thirty-nine dogs were given a second dose of DT/CSA, three each receiving a third or fourth dose. Eight dogs had a dose reduction (1.5 mg kg(-1)) and six dogs had treatment delays primarily for gastrointestinal toxicity. The overall response rate was 16.7% (8/48 had a partial response there were no complete responses). The highest response rate was seen in dogs with oral squamous cell carcinoma (50%; 6/12).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22905693/